A Real World Study to Capture Clinical and Patient Centered Outcomes in Adults with Severe Eosinophilic Asthma treated with Benralizumab. - EMPOWAIR

Study identifier:D3250R00102

ClinicalTrials.gov identifier:NCT05440656

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

A Real World Multicenter 48 week Prospective Cohort Study to Capture Clinical and Patient Centered Outcomes in Adults with Severe Eosinophilic Asthma Treated with Benralizumab in Routine Care Settings in Greece

Medical condition

Severe Eosinophilic Asthma

Phase

N/A

Healthy volunteers

No

Study drug

Cohort

Sex

All

Estimated Enrollment

150

Study type

Observational

Age

18 Years - 75 Years

Date

Study Start Date: 29 Jun 2022
Estimated Primary Completion Date: 30 Jun 2025
Estimated Study Completion Date: 30 Jun 2025

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Mar 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria